Brief: 2seventy bio Provides Update On KarMMa-9 Study And Previews Anticipated Strong Third Quarter Revenue Performance

2Seventy Bio

25/09/2024 11:02

Sept 25 (Reuters) - 2Seventy Bio Inc  TSVT.O :
    * 2SEVENTY BIO PROVIDES UPDATE ON KARMMA-9 STUDY AND
PREVIEWS
ANTICIPATED STRONG THIRD QUARTER REVENUE PERFORMANCE
    * 2SEVENTY BIO INC: 2SEVENTY AND BRISTOL MYERS SQUIBB
DISCONTINUE
ENROLLMENT IN PHASE 3 KARMMA-9 STUDY
    * 2SEVENTY BIO: DECISION RESULTS IN OVER $80 MILLION IN
ANTICIPATED COST SAVINGS OVER NEXT SEVERAL YEARS
    * 2SEVENTY BIO SEES Q3 ABECMA U.S. REVENUE GROWTH OF ABOUT
30%
FROM Q2 REVENUE OF $54 MILLION

Source text for Eikon:  ID:nBw4RmXp3a 
Further company coverage:  TSVT.O 

 ((Reuters.Briefs@thomsonreuters.com;))